Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPP 115

Next Previous
Search
Drug Profile

CPP 115

Alternative Names: CPP-115

Latest Information Update: 28 Nov 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University
  • Developer Catalyst Pharmaceuticals
  • Class Aminobutyric acids; Antiepileptic drugs; Carboxylic acids; Cyclopentanes; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gilles de la Tourette's syndrome
  • No development reported Infantile spasms; Partial epilepsies; Substance-related disorders

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Infantile spasms(In volunteers) in USA (PO)
  • 14 Mar 2018 Catalyst Pharmaceuticals has patent protection for CPP 115 in USA
  • 14 Mar 2018 Catalyst Pharmaceuticals has patents pending for CPP 115 in Japan, Canada and the European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top